scispace - formally typeset
J

J.M. Alonso

Researcher at University of Oviedo

Publications -  247
Citations -  5202

J.M. Alonso is an academic researcher from University of Oviedo. The author has contributed to research in topics: Power factor & Ballast. The author has an hindex of 35, co-authored 239 publications receiving 4889 citations.

Papers
More filters
Proceedings Article

Closed-loop regulated power supply for ozone generation based on buck converter and current-fed push-pull resonant inverter

TL;DR: In this article, the buck converter is used to regulate the output power against the line voltage variation, and to control the power delivered to the ozone generator (OG) by a push-pull inverter.
Proceedings ArticleDOI

Dimming in metal-halide and HPS lamps operating at HF: effects and modeling

TL;DR: In this article, a comparative analysis of dimming effects in metal halide and high pressure sodium (HPS) lamps is presented, where several lamps were characterized and electrical models were developed for their simulation in PSpice.
Proceedings ArticleDOI

Electronic ballast based on class E amplifier with a capacitive inverter and dimming for photovoltaic applications

TL;DR: In this article, the design and construction of an electronic ballast based on a class E amplifier with a capacitive impedance inverter and with dimming features is presented, which is intended to supply instant-start fluorescent lamps from a DC 12 V source.
Proceedings ArticleDOI

Design and experimental results of an input-current-shaper based electronic ballast

TL;DR: In this paper, the ICS is placed between the main rectifier and bulk capacitor to increase the conduction angle of the rectifier diodes up to a minimum value to obtain low current harmonics injected to the mains.
Journal ArticleDOI

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

TL;DR: BJ proteinuria at diagnosis is an independent variable of progression to MM that identifies a subgroup of high-risk SMM patients (51% risk of progression at 2 years) and ⩾500 mg of BJ proteinuria may allow, if validated in another series, to reclassify these patients to MM requiring therapy before the end-organ damage development.